Definitive Contract HHSN261201300076C

<p>This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Dxterity Diagnostics Incorporated. The contract is for the development of a blood test to predict radiation toxicity in patients treated with radiation therapy. The contract has a total potential value of $1,396,540.45 and a period of performance from September 19, 2016 to August 19, 2021. The contract is a cost-plus-fixed-fee Definitive Contract.</p>

This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services' National Institutes of Health, to Radiomedix, Inc., a small disadvantaged business. The contract, valued at $1,994,002.00, is for the development of targeted radionuclide therapy using 212Pb-octreotate analogs for the treatment of neuroendocrine tumors. The contract was awarded on September 18, 2018 and has a completion date of...

This $4,175,467 definitive cost-no-fee contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Pluri Biotech LTD, a for-profit limited liability company based in Israel, for the development of PLX-R18 cell therapy as a countermeasure for hematopoietic acute radiation syndrome. The contract, which has no set-aside designation, supports research and development efforts focused on creating safe and effective medical countermeasures to mitigate...

Ceramedix Holding, LLC was awarded a $4.22M cost-plus-fixed-fee definitive contract by the National Institute of Allergy and Infectious Diseases on July 1, 2023, to develop anticeramide treatment as a novel medical countermeasure for the acute effects of radiation exposure. The contract, with performance completing June 30, 2027, supports the NIH's broader mission to develop safe and effective countermeasures that reduce radiation-associated mortality and morbidity in mass casualty incidents....

This is a Small Business Innovation Research (SBIR) Phase III contract awarded by the Defense Health Agency (DHA) to Synedgen, Inc., a small business located in Claremont, California. The contract, valued at $2,297,415.00, is for the development of an &quot;optimized, field-stable glycopolymer-mimicking polysaccharide to prevent morbidity and mortality in exposure to ionizing radiation or nuclear injury.&quot; This contract builds upon earlier SBIR-funded research and is intended to deliver an...

The Defense Health Agency awarded a $3.0 million Phase II Small Business Innovation Research (SBIR) contract to Technology Holding LLC, a small business based in Salt Lake City, Utah, for the development of a novel biologic countermeasure for acute radiation syndrome. This 23-month effort, which commenced on June 21, 2022, and concludes October 20, 2026, is structured as a firm fixed-price definitive contract under the SBIR program's Phase II action, which supports innovative research and...

The Department of Health and Human Services' National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Pact &amp; Health LLC, a for-profit limited liability company located in Branford, Connecticut. The contract, awarded on September 11, 2019, has a potential value of $299,799.00 and is for the development of a versatile radiation-triggered phosphor platform for localized anti-cancer therapy. The contract is a...

This contract was awarded by the National Institutes of Health (NIH), which is part of the U.S. Department of Health and Human Services (HHS). It is a Small Business Innovation Research (SBIR) Phase II contract awarded to Mira DX Inc., a Woman-Owned Small Business (WOSB). The contract has a potential value of $1,999,999.00 and is a Firm Fixed Price contract. The contract was awarded under Topic 338 of the SBIR program, which is focused on &quot;Defining Normal Tissue and Tumor Biomarkers of...

The National Cancer Institute awarded a $250,000 firm fixed-price purchase order to Baylor College of Medicine on June 27, 2023, to support the US Pediatric Proton and Photon Therapy Cohort, a retrospective cohort study comparing the risks and benefits of proton versus photon radiation therapy in pediatric cancer patients. Under this non-set-aside contract, Baylor College of Medicine serves as the prime contractor with performance in Houston, Texas, and is scheduled to complete work by June...

This is a Department of the Army Medical Command Small Business Innovation Research (SBIR) Phase I contract awarded to Technology Holding LLC, a for-profit limited liability company focused on research and development across biotechnology, materials science, energy, and defense. The $249,970.74 firm-fixed-price contract is for a &quot;Novel Biologic Countermeasure for Acute Radiation Syndrome&quot; and was set aside for small businesses. Technology Holding has received prior federal contracts...